Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
The implementation of single use technology in the biopharmaceutical fill and finish process has seen a massive uptick recently because of better industry understanding, according to Pall’s Bruce Rawlings.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
Almac says its first leap into Next Generation Sequencing (NGS) data analysis services is a much needed-change from the industry’s current “one-size-fits-all” offering.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
The CRO industry is still considered a good long-term investment and the clinical services segment is set to continue its dominance thanks to sponsor R&D spending, says leading banker.
3M, the US-headquartered multinational, has launched a new range of bio filters which it says raise the benchmarks for flow-rate, organism reduction and efficiency across a range of applications.
EMD Millipore has opened a training facility in China as an education resource for the country’s rapidly expanding biopharmaceutical manufacturing and development sector.
The biomanufacturing industry needs to adopt an integrated approach to upstream and downstream processing to boost efficiency and productivity according to EMD Millipore.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
RXi and EyeGate lift the lid on ocular delivery of RNAi therapeutics for retinal disorders as the two firm’s team up to provide a unique needle-free solution.
Cost-effective, large-scale production of oncology drug Taxol (paclitaxel) intermediates could eventually be achieved using engineered Escherichia coli.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
Pall and New Brunswick have teamed up to develop and supply new disposable bioreactor technologies, targeting growing demand for products that improve quality and reduce cost of biomanufacturing.
Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.
ATMI is using Interphex 2010 to launch the Integrity PadReactor, a disposable bioreactor designed to provide a highly scalable entry point in its line of mixing and process manufacturing systems.
Access to Millipore’s UCOE expression technology though a new partnership is “step change” for customers, says contract manufacturing organization (CMO) Eden Biodesign.
Sartorius Stedim Biotech has introduced FlexAct BP, the first product in a range which will be an integrated single-use system for entire biomanufacturing steps in upstream and downstream processing.
CMO Avid Bioservices’ revenues rose by 74 per cent to $2.1m (€1.5m) in Q2, generating a further $7m from its parent company, and it has plans to boost output and become a leader in mammalian cell culture production.
Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.
The US contract manufacturing sector is strong enough to bounce back from any short-term slow down caused by the credit crisis, according to a new report by Frost & Sullivan (F&S).
Novozymes and Millipore have launched an animal-free culture supplement, which has been designed to reduce risk and regulatory pressures in upstream biopharmaceutical processes.
Pall Life Sciences has launched its Allegro 3D biocontainers, which have been designed to improve the performance of the company’s large-scale, single use manufacturing systems.
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Premier Pneumatics, GE Healthcare and WaterSep.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
the year.
Europe is tipped to witness the most significant worldwide gains in
biopharmaceutical manufacturing production capacity in the coming
years, despite an overall global decline in capacity utilisation by
the industry.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
Syft Technologies of New Zealand released the latest generation of
Selected Ion Flow Tube-Mass Spectrometry (SIFT) instrumentation at
Pittcon 2008 for the analysis of very low levels of organic
compounds in air (detection limits as...
Pharmaceutical manufacturers, distributors and retailers alike have
welcomed a unanimous vote by the California State Board of Pharmacy
to delay for another two years the implementation of electronic
pedigree requirements for tracking...
Bayer Healthcare is to deploy a new technique, developed by
Millipore, for genetically engineering cells to produce
pharmaceutically useful proteins that could both increase the yield
and accelerate drug production.
Artel has introduced a new feature for its Multichannel
Verification System (MVS), which includes an automation function
that allows for time savings and reducing human error.
Cellexus Biosystems, the UK company that designs, manufactures and
sells disposable cell growth technology for the biopharmaceutical
industry, is extending the rental plan offered on its CellMaker
Lite2 single-use bioreactor in response...
